CN113355259A - Lactobacillus gasseri and application thereof in treating peptic ulcer - Google Patents
Lactobacillus gasseri and application thereof in treating peptic ulcer Download PDFInfo
- Publication number
- CN113355259A CN113355259A CN202110315930.6A CN202110315930A CN113355259A CN 113355259 A CN113355259 A CN 113355259A CN 202110315930 A CN202110315930 A CN 202110315930A CN 113355259 A CN113355259 A CN 113355259A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus gasseri
- ttys
- microbial agent
- ulcer
- lactobacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000186606 Lactobacillus gasseri Species 0.000 title claims abstract description 71
- 208000008469 Peptic Ulcer Diseases 0.000 title claims abstract description 10
- 208000011906 peptic ulcer disease Diseases 0.000 title claims abstract description 9
- 230000000813 microbial effect Effects 0.000 claims abstract description 26
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 24
- 238000004321 preservation Methods 0.000 claims abstract description 11
- 244000005700 microbiome Species 0.000 claims abstract description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 13
- 239000001963 growth medium Substances 0.000 claims description 9
- 238000000855 fermentation Methods 0.000 claims description 8
- 230000004151 fermentation Effects 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 6
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 4
- 235000020183 skimmed milk Nutrition 0.000 claims description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- 229920001817 Agar Polymers 0.000 claims description 3
- 239000001888 Peptone Substances 0.000 claims description 3
- 108010080698 Peptones Proteins 0.000 claims description 3
- 239000008272 agar Substances 0.000 claims description 3
- 235000015278 beef Nutrition 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000009630 liquid culture Methods 0.000 claims description 3
- 235000019319 peptone Nutrition 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008176 lyophilized powder Substances 0.000 claims description 2
- 238000009629 microbiological culture Methods 0.000 claims description 2
- 239000002054 inoculum Substances 0.000 claims 3
- 208000025865 Ulcer Diseases 0.000 abstract description 23
- 231100000397 ulcer Toxicity 0.000 abstract description 23
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract description 21
- 208000007107 Stomach Ulcer Diseases 0.000 abstract description 12
- 201000005917 gastric ulcer Diseases 0.000 abstract description 11
- 238000000034 method Methods 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 241000700159 Rattus Species 0.000 description 16
- 210000002784 stomach Anatomy 0.000 description 14
- 210000001156 gastric mucosa Anatomy 0.000 description 12
- 210000002919 epithelial cell Anatomy 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical group CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 7
- 229960003174 lansoprazole Drugs 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 208000032843 Hemorrhage Diseases 0.000 description 6
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 6
- 210000004877 mucosa Anatomy 0.000 description 6
- 230000017074 necrotic cell death Effects 0.000 description 6
- 230000007850 degeneration Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 description 2
- 101001076687 Lactobacillus gasseri Inulosucrase Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000002327 eosinophilic effect Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229940017800 lactobacillus casei Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 210000004876 tela submucosa Anatomy 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 238000012371 Aseptic Filling Methods 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000509544 Lactobacillus gallinarum Species 0.000 description 1
- 241001662087 Lactobacillus gasseri ATCC 33323 = JCM 1131 Species 0.000 description 1
- 241000834881 Lactobacillus gasseri CECT 5714 Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 201000000660 Pyloric Stenosis Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000008576 chronic process Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000004609 intestinal homeostasis Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000004018 waxing Methods 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/145—Gasseri
Abstract
The invention relates to the field of microorganisms, and particularly relates to lactobacillus gasseri and application thereof in treating peptic ulcer. The Lactobacillus gasseri (Lactobacillus gasseri) TTYS-839 is preserved in the common microorganism center of China Committee for culture Collection of microorganisms at 7.2.2020, is classified and named as Lactobacillus gasseri (CGMCC) with the preservation number of CGMCC No.20178 and the preservation address of the institute of microbiology of China academy of sciences No. 3, North Cheng Lu No. 1 of the sunward area in Beijing. The invention also provides a microbial agent containing the Lactobacillus gasseri TTYS-839, and the microbial agent is fed to a gastric ulcer rat prepared by an acetic acid wet application method, so that the ulcer area and the ulcer volume can be obviously reduced, and the microbial agent has an obvious treatment effect on gastric ulcer.
Description
Technical Field
The invention relates to the field of microorganisms, and particularly relates to lactobacillus gasseri and application thereof in treating peptic ulcer.
Background
Peptic ulcer is a common chronic disease, can occur near the anastomoses of esophagus, stomach, duodenum and stomach-jejunum, and is mainly manifested as abdominal pain, chronic process and periodic attack. The disease is caused by pyloric helicoidal infection, long-term use of medicine, genetic susceptibility, stress, smoking, long-term mental stress and other reasons or inducement, the balance between the erosion ability of gastric acid and pepsin and the defense ability of mucosa is lost, and gastric acid and pepsin can produce self digestion on mucosa to cause disease. The existing treatment mainly comprises an acid inhibitor and can eradicate the helicobacter pylori infection, the bismuth agent mainly protects the gastric mucosa, but patients often suffer from recurrent-remitting periodic attacks and can bleed, perforate, pyloric obstruction and even cancerate in severe cases, and the disease needs a new method for treating the disease. Research shows that the probiotics as a microecological regulator can reduce harmful bacteria in the stomach and intestine, produce beneficial nutrient substances and protect the structural and functional integrity of the gastrointestinal mucosa. In recent years, probiotics have become novel, natural therapeutic drugs and foods for the treatment of peptic ulcers.
In 2010, 15 probiotic strains which can be used for food are approved by the Ministry of health of China. Lactobacillus gasseri belongs to one of them, which is a ubiquitous human commensal bacterium widely present on the oral, small, large, and vaginal mucosa of normal persons, and has established safety in healthy persons (Kurt Selle, Todd R. Klaenhamme, Genomic and phenotypic evaluation for biological infections of Lactobacillus gasseri on human health. FEMS Microbiology Reviews, Volume 37, Issue 6, November 2013, Pages 915. 935). Is also one of the listed safe strains of the Food and Drug Administration (FDA). The research shows that: it can maintain human intestinal homeostasis, maintain vaginal health, prevent allergic reactions, inhibit infection by helicobacter pylori, and alleviate symptoms caused by viral infection (Kurt Selle, Todd R. Klaenhamme, Genomic and phenotypic evidence for pathological infections of Lactobacillus gasseri on human health. FEMS Microbiology Reviews, Volume 37, Issue 6, November 2013, Pages 915-935). However, the combination of Lactobacillus gasseri CECT5714 and Lactobacillus gallinarum CECT5711 stimulates NK cells and increases secretory IgA levels, but this effect is not observed for either Lactobacillus gasseri ATCC 33323 or Lactobacillus gasseri TMC0356 (see in particular Olivares M D i a z-Roero MAP G Lo mez N Lara-Villossa F silicon S Maldono Mart i R L pez-Huertas Erodr i z JM & Xaus J (2006a) Oral administration of two biological strains, Lactobacillus gasseri CT5714 and Lactobacillus coryformis CECT5711, Escherichia the interanl functional absorption of bacteria additives J184107 and Lactobacillus casei S2011K S K A3547K 4. coli J184104 and Lactobacillus casei K. This indicates that its specific function is strain specific. Therefore, there remains a need for isolated cultures and characterization of new strains and for scale-up production to treat or assist in the treatment of digestive disorders.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provides a lactobacillus gasseri strain and application thereof in treating peptic ulcer.
In order to achieve the purpose, the invention adopts the technical scheme that: providing a strain of Lactobacillus gasseri (Lactobacillus gasseri) TTYS-839, wherein the Lactobacillus gasseri (Lactobacillus gasseri) TTYS-839 is preserved in the China general microbiological culture Collection center at 7.2.2020, is named as Lactobacillus gasseri (Lactobacillus gasseri) by classification, the preservation number is CGMCC No.20178, and the preservation address is the institute of microbiology of China academy of sciences No. 3, North China institute of sciences, west road 1 of the Korean district, Beijing. The invention also provides application of the Lactobacillus gasseri TTYS-839 in preparation of medicines or foods for treating peptic ulcer.
As a preferred embodiment of the application of the invention, the medicament comprises a pharmaceutically effective dose of the Lactobacillus gasseri TTYS-839 and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier is preferably a mixture of one or more of skimmed milk, lactose, glucose, sucrose, sorbitol, mannose, trehalose, starch, acacia, calcium phosphate, alginate, gelatin, calcium silicate, fine crystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate or mineral oil.
The invention also provides a microbial agent containing the Lactobacillus gasseri TTYS-839.
As a preferred embodiment of the microbial agent of the present invention, the microbial agent is a tablet, a capsule, an oral liquid or a lyophilized powder.
In a preferred embodiment of the microbial agent of the present invention, the microbial agent is obtained by fermenting Lactobacillus gasseri TTYS-839 according to claim 1.
As a preferred embodiment of the microbial agent of the present invention, the fermentation specifically comprises: inoculating the seed solution of Lactobacillus gasseri TTYS-839 into the fermentation liquid at a ratio of 5-8%, culturing at 28-35 deg.C under stirring for 48-72 hr until pH is reduced to 4.0-4.5 and viable Lactobacillus gasseri per ml is 3 × 108～4×108And (4) obtaining the microbial agent.
As a preferred embodiment of the microbial agent of the present invention, the fermentation broth comprises the following components: 0.5-3% of glucose, 1-4% of peptone, 1-2% of sodium chloride, 0.2-0.4% of dipotassium hydrogen phosphate, 15-20% of skim milk and 0.2-0.4% of sodium alginate.
As a preferred embodiment of the microbial agent, the seed solution of Lactobacillus gasseri TTYS-839 is inoculated on a slant culture medium and cultured for 36-48h at 28-35 ℃ to obtain a slant culture; inoculating the cultured slant culture into liquid culture medium, and culturing at 28-35 deg.C for 40-48h to obtain seed liquid.
In a preferred embodiment of the microbial agent of the present invention, the culture medium of lactobacillus gasseri TTYS-839 comprises the following components per L: 0.5-3% of glucose, 1-3% of beef extract, 1-2% of sodium chloride, 0.2-0.4% of dipotassium hydrogen phosphate and 15g of agar, and the pH value is 5-6.
The invention has the beneficial effects that:
(1) the invention screens and separates a strain of Lactobacillus gasseri from intestinal flora of healthy human body, and the strain is named as Lactobacillus gasseri TTYS-839. The microbial agent containing the Lactobacillus gasseri TTYS-839 is provided, and the microbial agent is fed to a gastric ulcer rat prepared by an acetic acid wet-dressing method, so that the ulcer area and the ulcer volume can be obviously reduced, and the gastric ulcer can be obviously treated.
(2) By utilizing the production method, the large-scale production of the microbial agent containing the lactobacillus gasseri TTYS-839 can be safely, efficiently and stably carried out.
Biological material preservation
The Lactobacillus gasseri (Lactobacillus gasseri) TTYS-839 is preserved in the common microorganism center of China Committee for culture Collection of microorganisms at 7.2.2020, is classified and named as Lactobacillus gasseri (CGMCC) with the preservation number of CGMCC No.20178 and the preservation address of the institute of microbiology of China institute of academy of sciences No. 3, North Cheng West Lu No. 1 of the sunward area in Beijing.
Drawings
FIG. 1: blank rat stomach HE staining result graph.
FIG. 2: model group rat stomach HE staining results.
FIG. 3: and (3) a Lansoprazole group rat stomach HE staining result graph.
FIG. 4: and the result of HE staining on the stomach of rats in a dose group of 2mL/100g of culture solution TTYS-839 of lactobacillus gasseri is shown.
FIG. 5: and 4mL of Lactobacillus gasseri TTYS-839 culture solution per 100g of dose group rat stomach HE staining result chart.
FIG. 6: and the result of HE staining on the stomach of rats in a dose group of 8mL/100g of culture solution TTYS-839 of lactobacillus gasseri is shown.
Detailed Description
To more clearly illustrate the technical solutions of the present invention, the following embodiments are further described, but the present invention is not limited thereto, and these embodiments are only some examples of the present invention.
EXAMPLE 1 screening and culture of the strains
Screening and separating a strain from healthy human intestinal flora, wherein the strain has a 16s RNA sequence shown as SEQ ID NO. 1, the length of the sequence is 1510bp, and the strain is identified as Lactobacillus gasseri by comparing the sequence to be detected with genes in Genbank. The inventors named it as Lactobacillus gasseri (Lactobacillus gasseri) TTYS-839.
The Lactobacillus gasseri TTYS-839 is preserved in the common microorganism center of China Committee for culture Collection of microorganisms at 7.2.2020, is classified and named as Lactobacillus gasseri, has the preservation number of CGMCC No.20178 and the preservation address of the institute of microbiology of China academy of sciences No. 3 of West Lu 1 of the sunward district, Beijing.
Example 2 treatment of gastric ulcers with Lactobacillus gasseri TTYS-839
A rat is used as a model animal, a gastric ulcer animal model is constructed by an acetic acid wet application method, and the treatment condition of TTYS-839 on gastric ulcer is researched.
1. Laboratory animal
SD rat, male, 180-. A breeding environment: the temperature is 22 +/-2 ℃, the humidity is 45-65%, and the day and night alternate for 12 hours; can be taken freely and drunk freely.
2. Experimental methods
(1) Molding die
After the rats are adaptively raised for 7 days, the animals are fasted for 24 hours without water supply, the abdominal cavity is cut under the xiphoid process after ether anesthesia, the stomach is slightly pulled out of the abdominal cavity, a circular filter paper sheet with the diameter of 5mm is used for soaking a proper amount of acetic acid, the serosal layer of the antrum of the stomach is pasted for 10s three times, the incision is sutured, and the animals are raised in a single cage for 3 days after the operation.
(2) Grouping and administration of drugs
48 rats which are successfully operated are selected and randomly divided into a control group, a model group, a lactobacillus gasseri TTys-839 culture solution 2mL/100g group, a lactobacillus gasseri TTys-839 culture solution 4mL/100g group, a lactobacillus gasseri TTys-8 mL/100g group and a lansoprazole 5mg/kg group according to the body weight, and each group comprises 8 rats. Each group was gavaged with the corresponding dose for 28 consecutive days. The model group was perfused with normal saline at a dose of 2mL/100 g.
The production method of the lactobacillus gasseri TTYS-839 culture solution comprises the following steps:
culture medium of Lactobacillus gasseri TTYS-839: 0.5-3% of glucose, 1-3% of beef extract, 1-2% of sodium chloride, 0.2-0.4% of dipotassium hydrogen phosphate, 15g of agar and 1L of distilled water, wherein the pH value is 5-6; inoculating bacteria on the slant culture medium, and culturing at 28-35 deg.C for 36-48h to obtain slant culture; inoculating the cultured fresh slant cultureCulturing in the liquid culture medium at 28-35 deg.C for 40-48 hr to obtain seed solution; then inoculating the cultured seed solution into a fermentation tank according to the proportion of 5-8%; adding purified water into fermentation tank, adding 0.5-3% glucose, 1-4% peptone, 1-2% sodium chloride, 0.2-0.4% dipotassium hydrogen phosphate, 15-20% skimmed milk, 0.2-0.4% sodium alginate, heating at high temperature, maintaining at 120 deg.C for 20-30min, cooling to room temperature, inoculating seed solution at 5-8%, stirring at 28-35 deg.C for 48-72 hr, and culturing until pH is reduced to 4.0-4.5, wherein the number of viable Lactobacillus gasseri per ml is 3 × 108～4×108Transferring to an aseptic filling production line at room temperature, filling and sealing.
(3) Taking materials
After the last administration, the animal is fasted for 12 hours, weighed, killed, the whole stomach is taken out and soaked in 10% formaldehyde, after 20 minutes of soaking, the stomach is cut along the greater curvature of the stomach, the content is cleaned, the glandular stomach area is spread and laid on a glass plate, the water in the ulcer is sucked dry by paper, and the area and the volume of the ulcer are measured. After the gross examination, the most severely damaged part of the gastric mucosa of each animal was excised, HE-stained according to the kit instructions, and observed under the microscope. Note that the normal transverse section of the gastric mucosa, including the observation of the entire layer of mucosa, was selected.
3. Detecting the index
(1) Observing and recording ulcer area and volume
Ulcer area measurement method: the number of squares occupied by the ulcer was counted under a dissecting microscope with a scale and converted into the area.
Volume measurement: injecting the colored ink into the ulcer by using a micro-syringe, filling the ulcer to be flush with the periphery, and reading the scale on the micro-syringe to obtain the volume of the ulcer.
(2) Pathological histological observation of ulcer part section
The most severely damaged parts of the gastric mucosa of each animal were excised, fixed in 4% paraformaldehyde for 2 days, placed in plastic embedding boxes, labeled, and rinsed overnight with running water. The gastric tissue after flushing is dehydrated, transparent and waxed, and after the waxing is finished, the gastric tissue is stored in a refrigerator at 4 ℃. The wax block was trimmed and then clamped in a paraffin slicer to cut into sections with a thickness of 5 μm. The cut tissue slices are put into a water bath kettle at 40 ℃ for flattening, and the slices are fished by an anti-falling glass slide. Then, the slide is placed in an oven at 60 ℃ for baking for 2 hours, and hydration, dyeing and mounting are carried out according to the specification of an HE dyeing kit. And (4) observing under a mirror.
4. Statistical analysis
Data were analyzed using SPSS 21.0 analytical software and results are expressed as mean ± standard deviation (mean ± SD). Comparisons between sets of means the overall variance differences were evaluated using One-Way analysis of variance (One-Way ANOVA) and multiple comparisons were performed with LSD. For the comparison between the two groups, a non-paired t-test was used for comparison. Defining P <0.05 as significant difference.
5. Results of the experiment
(1) Measurement of ulcer area and ulcer volume
The results are shown in table 1, compared with the control group, the ulcer area and the ulcer volume of the model group are obviously increased, which indicates that the gastric ulcer model is successfully prepared; compared with a model group, the ulcer areas of the lansoprazole group and the lactobacillus gasseri TTYS-839 in the 4mL/100g dose group are obviously reduced, and the doses of the lactobacillus gasseri TTYS-839 in 2mL/100g and 8mL/100g are not significant; compared with a model group, ulcer volumes of 2mL/100g and 4mL/100g dose groups of the lansoprazole group and the Lactobacillus gasseri TTYS-839 are obviously reduced and are in a dose-effect relationship; the ulcer volume of the 8mL/100g dose group of Lactobacillus gasseri TTYS-839 is also significantly reduced. The results show that the lactobacillus gasseri TTYS-839 has a treatment effect on the gastric ulcer model prepared by the acetic acid wet application method.
TABLE 1 therapeutic effect of TTYS-839 culture on ulcer area and ulcer volume in rats (mean + -SD)
Note: p < 0.01vs. control; model group with # P <0.05, # P < 0.01vs
(2) Rat body weight measurement
As shown in Table 2, the weight change of the model group was not significant as compared with that of the control group, and it was confirmed that the gastric ulcer model prepared by the acetic acid wet dressing method had no effect on the weight of the rat. Compared with the model group, the weight change of the lansoprazole group and the lactobacillus gasseri TTYS-839 in the dose groups of 2mL/100g and 4mL/100g is not significant; the group weight was significantly reduced in the 8mL/100g dose, possibly associated with reduced feeding.
TABLE 2 Effect of Lactobacillus gasseri TTYS-839 culture on weight of gastric ulcer rats
Note: p < 0.01vs. control; model group with # P <0.05, # P < 0.01vs
(3) Pathological histological observation of ulcer part section
As shown in figure 1, the blank group has clear structure of each layer of the tissue, abundant gastric glands, normal epithelial cell morphology, no obvious congestion, hemorrhage and epithelial cell degeneration necrosis;
as shown in fig. 2, the tissue of the model group has local mucosal epithelium loss, the number of gastric glands is reduced, connective tissue is proliferated (arrow (r)), muscle fiber cells of muscular layer disappear, the muscle fiber cells are replaced by the proliferated connective tissue (arrow (r)), and a small amount of lymphocyte infiltration (arrow (c)) is accompanied, blood stasis of blood vessel (arrow (r)) appears, bleeding is partially visible (arrow (c)), and obvious hyperemia and epithelial cell degeneration and necrosis are not seen;
as shown in fig. 3, the lansoprazole group has clear tissue layer structure, abundant gastric glands and close arrangement, eosinophilic mass (arrow) can be seen in a small amount of gastric glands, extravasated blood (arrow) can be seen locally, and obvious congestion, hemorrhage and epithelial cell degeneration necrosis can not be seen;
as shown in fig. 4, the tissue layers of the 2mL/100g dose group have clear structures, local mucosal epithelial cells are absent (arrow b), the number of gastric glands is rich, the morphology of epithelial cells is normal, a small amount of eosinophilic masses (arrow ninx) can be seen in the gastric glands, a small amount of blood vessel congestion (arrow c) is not seen, and obvious hyperemia, hemorrhage and epithelial cell degeneration necrosis are not seen;
as shown in fig. 5, each layer of the tissue of the 4mL/100g dose group has clear structure, local mucosal epithelial cells are exfoliated (arrow a), a small amount of blood stasis in the mucosal layer and the submucosa (arrow B) is generated, the number of gastric glands is rich, the morphology of epithelial cells is normal, and no obvious hemorrhage or degeneration and necrosis of epithelial cells are observed;
as shown in fig. 6, the tissue of the 8mL/100g dose group had more mucosal epithelium missing (arrow C), more irregular arrangement of gastric glands, disappearance of myofibroblasts of the muscular layer, replacement by hyperplastic connective tissue (arrow D), with a small amount of lymphocyte infiltration (arrow E), bleeding locally visible (arrow F), no visible congestion and no degenerative necrosis of epithelial cells.
TABLE 3 number of animals with small amount of blood stasis (lesion) in mucosa and submucosa in each experimental group
| Group of | Animal number (number) |
| |
1 |
| Model set | 9 |
| |
4 |
| TTYS-839 Low dose group | 7 |
| TTYS-839 |
4 |
| TTYS-839 |
5 |
6. Conclusion of the experiment
The results are combined to discover that the culture solution of the lactobacillus gasseri TTYS-839 has a treatment effect on a gastric ulcer model prepared by an acetic acid wet application method.
Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting the protection scope of the present invention, and although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
SEQUENCE LISTING
<110> Sun Changchun
<120> lactobacillus gasseri strain and application thereof in treatment of peptic ulcer
<130> 2021.03.19
<160> 1
<170> PatentIn version 3.5
<210> 1
<211> 1510
<212> DNA
<213> Artificial Synthesis
<400> 1
ggctcaggac gaacgctggc ggcgtgccta atacatgcaa gtcgagcgag cttgcctaga 60
tgaatttggt gcttgcacca aatgaaacta gatacaagcg agcggcggac gggtgagtaa 120
cacgtgggta acctgcccaa gagactggga taacacctgg aaacagatgc taataccgga 180
taacaacact agacgcatgt ctagagttta aaagatggtt ctgctatcac tcttggatgg 240
acctgcggtg cattagctag ttggtaaggt aacggcttac caaggcaatg atgcatagcc 300
gagttgagag actgatcggc cacattggga ctgagacacg gcccaaactc ctacgggagg 360
cagcagtagg gaatcttcca caatggacgc aagtctgatg gagcaacgcc gcgtgagtga 420
agaagggttt cggctcgtaa agctctgttg gtagtgaaga aagatagagg tagtaactgg 480
cctttatttg acggtaatta cttagaaagt cacggctaac tacgtgccag cagccgcggt 540
aatacgtagg tggcaagcgt tgtccggatt tattgggcgt aaagcgagtg caggcggttc 600
aataagtctg atgtgaaagc cttcggctca accggagaat tgcatcagaa actgttgaac 660
ttgagtgcag aagaggagag tggaactcca tgtgtagcgg tggaatgcgt agatatatgg 720
aagaacacca gtggcgaagg cggctctctg gtctgcaact gacgctgagg ctcgaaagca 780
tgggtagcga acaggattag ataccctggt agtccatgcc gtaaacgatg agtgctaagt 840
gttgggaggt ttccgcctct cagtgctgca gctaacgcat taagcactcc gcctggggag 900
tacgaccgca aggttgaaac tcaaaggaat tgacgggggc ccgcacaagc ggtggagcat 960
gtggtttaat tcgaagcaac gcgaagaacc ttaccaggtc ttgacatcca gtgcaaacct 1020
aagagattag gtgttccctt cggggacgct gagacaggtg gtgcatggct gtcgtcagct 1080
cgtgtcgtga gatgttgggt taagtcccgc aacgagcgca acccttgtca ttagttgcca 1140
tcattaagtt gggcactcta atgagactgc cggtgacaaa ccggaggaag gtggggatga 1200
cgtcaagtca tcatgcccct tatgacctgg gctacacacg tgctacaatg gacggtacaa 1260
cgagaagcga acctgcgaag gtaagcggat ctctgaaagc cgttctcagt tcgaactgta 1320
ggctgcaact cgcctacacg aagctggaat cgctagtaat cgcggatcag cacgccgcgg 1380
tgaatacgtt cccgggcctt gtacacaccg cccgtcacac catgagagtc tgtaacaccc 1440
aaagccggtg ggataacctt tataggagtc agccgtctaa ggtaggacag atgattaggg 1500
tgaagtcgta 1510
Claims (10)
1. The Lactobacillus gasseri (Lactobacillus gasseri) TTYS-839 is characterized in that the Lactobacillus gasseri (Lactobacillus gasseri) TTYS-839 has been preserved in the China general microbiological culture Collection center of the culture Collection of microorganisms at 7.2.2020, is classically named as Lactobacillus gasseri (Lactobacillus gasseri), has the preservation number of CGMCC No.20178 and has the preservation address of the institute of microbiology of China institute of academy of sciences No. 3, west road 1 of North America of the Yangtze district of Beijing city.
2. Use of lactobacillus gasseri TTYS-839 according to claim 1 in the manufacture of a medicament or food product for the treatment of peptic ulcer.
3. The use of claim 2, wherein said medicament comprises a pharmaceutically effective amount of said lactobacillus gasseri TTYS-839 and a pharmaceutically acceptable carrier.
4. A microbial inoculant comprising lactobacillus gasseri TTYS-839 of claim 1.
5. The microbial agent according to claim 4, wherein the microbial agent is a tablet, a capsule, an oral liquid or a lyophilized powder.
6. The microbial agent according to claim 4, wherein the microbial agent is obtained by fermenting Lactobacillus gasseri TTYS-839 of claim 1.
7. The microbial inoculant according to claim 6, wherein the fermentation is in particular: inoculating the seed solution of Lactobacillus gasseri TTYS-839 into the fermentation liquid at a ratio of 5-8%, culturing at 28-35 deg.C under stirring for 48-72 hr until pH is reduced to 4.0-4.5 and viable Lactobacillus gasseri per ml is 3 × 108～4×108And (4) obtaining the microbial agent.
8. The microbial inoculant according to claim 7, wherein the fermentation broth comprises the following components: 0.5-3% of glucose, 1-4% of peptone, 1-2% of sodium chloride, 0.2-0.4% of dipotassium hydrogen phosphate, 15-20% of skim milk and 0.2-0.4% of sodium alginate.
9. The microbial agent according to claim 7, wherein the seed solution of Lactobacillus gasseri TTYS-839 is inoculated on a slant culture medium, and cultured for 36-48h at 28-35 ℃ to obtain a slant culture; inoculating the cultured slant culture into liquid culture medium, and culturing at 28-35 deg.C for 40-48h to obtain seed liquid.
10. The microbial agent according to claim 9, wherein the culture medium of lactobacillus gasseri TTYS-839 comprises the following components per L: 0.5-3% of glucose, 1-3% of beef extract, 1-2% of sodium chloride, 0.2-0.4% of dipotassium hydrogen phosphate and 15g of agar, and the pH value is 5-6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110315930.6A CN113355259A (en) | 2021-03-24 | 2021-03-24 | Lactobacillus gasseri and application thereof in treating peptic ulcer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110315930.6A CN113355259A (en) | 2021-03-24 | 2021-03-24 | Lactobacillus gasseri and application thereof in treating peptic ulcer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113355259A true CN113355259A (en) | 2021-09-07 |
Family
ID=77525010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110315930.6A Pending CN113355259A (en) | 2021-03-24 | 2021-03-24 | Lactobacillus gasseri and application thereof in treating peptic ulcer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113355259A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114561313A (en) * | 2021-08-26 | 2022-05-31 | 广州维生君生物科技有限公司 | Lactobacillus gasseri and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001002578A (en) * | 1999-06-24 | 2001-01-09 | Yasuhiro Koga | Helicobacter pylori-removing medicament |
| US20010021393A1 (en) * | 1997-04-11 | 2001-09-13 | Yoshikatsu Kodama | Specific antibodies for use in preparation of pharmaceutical compositions useful in the prevention or treatment of gastritis, gastric ulcers and duodenal ulcers |
| CN104839693A (en) * | 2015-04-23 | 2015-08-19 | 劲膳美生物科技股份有限公司 | Medical formula food for people suffering from gastric ulcer and duodenal ulcer |
| CN108403725A (en) * | 2018-05-22 | 2018-08-17 | 台州市劢康生物科技有限公司 | Composition for treating digestive tract ulcer and its application |
| CN112469812A (en) * | 2018-05-23 | 2021-03-09 | Ko生物技术有限公司 | Lactobacillus gasseri KBL697 strain and application thereof |
-
2021
- 2021-03-24 CN CN202110315930.6A patent/CN113355259A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010021393A1 (en) * | 1997-04-11 | 2001-09-13 | Yoshikatsu Kodama | Specific antibodies for use in preparation of pharmaceutical compositions useful in the prevention or treatment of gastritis, gastric ulcers and duodenal ulcers |
| JP2001002578A (en) * | 1999-06-24 | 2001-01-09 | Yasuhiro Koga | Helicobacter pylori-removing medicament |
| CN104839693A (en) * | 2015-04-23 | 2015-08-19 | 劲膳美生物科技股份有限公司 | Medical formula food for people suffering from gastric ulcer and duodenal ulcer |
| CN108403725A (en) * | 2018-05-22 | 2018-08-17 | 台州市劢康生物科技有限公司 | Composition for treating digestive tract ulcer and its application |
| CN112469812A (en) * | 2018-05-23 | 2021-03-09 | Ko生物技术有限公司 | Lactobacillus gasseri KBL697 strain and application thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114561313A (en) * | 2021-08-26 | 2022-05-31 | 广州维生君生物科技有限公司 | Lactobacillus gasseri and application thereof |
| CN114561313B (en) * | 2021-08-26 | 2022-09-13 | 佛山市孛特碧欧微生物科技有限公司 | Lactobacillus gasseri and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111235070B (en) | Breast milk infant source lactobacillus plantarum BF _15 and application thereof | |
| CN110144304B (en) | Lactobacillus casei strain and application thereof | |
| CN100591756C (en) | Acidproof and bile-salt-resisting rhamnose lactobacillus strain with anti-enterovirus and antioxidant functions | |
| CN111011856A (en) | Composition for relieving gastropathy, preparation method thereof and food for relieving gastropathy | |
| CN113755409B (en) | Bifidobacterium longum for relieving insulin resistance and application thereof | |
| CN112218646A (en) | Composition and application thereof | |
| CN114107134B (en) | Brevibacillus laterosporus and application thereof | |
| CN117143766A (en) | Lactobacillus paracasei for repairing enteric nerves and application thereof | |
| CN113549567B (en) | Lactobacillus rhamnosus NSL0401 with defecation promoting function and application thereof | |
| CN116814510B (en) | Lactobacillus rhamnosus OPB41 capable of preventing or improving Alzheimer's disease and application thereof | |
| CN113355259A (en) | Lactobacillus gasseri and application thereof in treating peptic ulcer | |
| CN112574924B (en) | Bacillus subtilis strain, microecological preparation and application thereof | |
| CN111743158B (en) | Probiotic tablet with function of enhancing immunity and preparation method thereof | |
| CN109207389B (en) | Thrombolytic lipid-lowering probiotic compound bacteria traditional Chinese medicine oral liquid and preparation method thereof | |
| CN116083325B (en) | Lactobacillus rhamnosus for improving helicobacter pylori related gastrointestinal diseases and application thereof | |
| CN116179440B (en) | Bacillus gallinarum and application thereof | |
| CN117004503B (en) | Saliva combined lactobacillus MB1 and application thereof in preparation of food and medicine for assisting sleep and regulating intestines and stomach | |
| CN115466699B (en) | Panda-derived lactobacillus salivarius and application thereof in treating or preventing inflammatory bowel diseases | |
| WO2018112740A1 (en) | Lactobacillus gasseri, culture method therefor and application thereof | |
| CN116555075A (en) | Lactobacillus plantarum JF1 and application thereof in preparation of anti-aging food and drug | |
| CN109874329B (en) | Fusarium butyricum and culture method and application thereof | |
| CN112795508B (en) | Enterococcus faecium YQH2 and application thereof | |
| CN115851538B (en) | Wessella enteroides MbWp-171 and product and application thereof | |
| CN116606761B (en) | Bifidobacterium animalis subspecies BLa19 capable of relieving rheumatoid arthritis and application thereof | |
| CN115851537B (en) | Enteromorpha Weissella MbWp-142, product and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210907 |
|
| RJ01 | Rejection of invention patent application after publication |